Pharmaceutical companies are increasingly relying on biomarkers to deliver precision medicine in immuno-oncology. Biomarkers can accelerate drug development and reduce the overall cost; they also allow sponsors to identify failed treatments sooner so that resources are not wasted on expensive, late-stage trials with unsafe or inactive compounds. Finally, these tests …
![Opportunities for Biomarkers in Immuno-Oncology](https://ddblog.labcorp.com/wp-content/uploads/2018/03/Opportunities-for-Biomarkers-in-Immuno-Oncology.jpg)